Company: DARE
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0001401914-25-000014
Chunk: 32

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 32
---
 |     |              |       — |     |                                           |  76,000 |     |                 | 290,624 |     |       |   398,291 |
| Former Chief Financial Officer        |     |   2023 |     |        | 380,000 |     |       | — |     |              | 278,791 |     |                                           |  76,000 |     |                 |  13,200 |     |       |   747,991 |

(1) The amounts in this column represent the grant date fair value, determined in accordance with ASC Topic 718, Compensation-Stock Compensation (ASC Topic 718), of stock options granted to the applicable individual. See Note 10. Stock-Based Compensation to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025 for details as to the assumptions used to determine the fair value of the awards .

(2) The amounts in this column represent performance-based incentive compensation earned for the years indicated.

(3) The amounts in this column represent the Company's matching contributions under the Company's 401(k) plan. In addition, with regards to Ms. Walters-Hoffert, the amount in this column for 2024 includes reimbursements of medical insurance premiums and $285,003 paid for consulting services, in each case, under her consulting agreement. The Company provides the named executive officers with health, medical and other non-cash benefits generally available to all employees, which are not reflected in this table pursuant to SEC rules.

(4) Ms. Walters-Hoffert retired and her employment with us ended on January 26, 2024.

#### Narrative to Summary Compensation Table
As reflected in the table above, the 2024 compensation of our named executive officers consisted of three primary components: (1) base salary; (2) equity compensation exclusively in the form of stock options; and (3) performance-based incentive compensation.

Base Salary . The 2024 annual base salary of our named executive officers was as reported in the "salary" column of the summary compensation table. Ms. Haring-Layton’s annual base salary was increased from $295,000 to $330,000 in connection with her promotion from our Vice President, Accounting & Finance to our Chief Accounting Officer.

Option Awards . In March 2024, we granted to Ms. Johnson a stock option to purchase